Brain Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Magnetic Resonance Spectroscopy, PET Scan, Spinal Tap, Magnetic Resonance Imaging), By Brain Cancer Type (Acoustic Neuroma, Astrocytomas, Chordomas, Ependymomas), And Segment Forecasts, 2019 To 2025

The global brain cancer diagnostics market size is projected to grow at a double-digit CAGR for the forecast period. The market size drivers for the growth of brain cancer diagnostics are expected to propel by technological developments and improvements in diagnostics machines. Additionally, the significance of the rise of brain cancer is expected to grow globally in the upcoming years. The rise in the number of cigarette smokers responsible for brain cancer has contributed to the market size. However, major restraints comprise heavy costs associated with diagnosis, low awareness levels, and lesser accessibility.

A brain tumor occurs with the formation of abnormal cells inside the brain. Hence, there are two types of tumors, malignant or cancerous tumors, and benign tumors. Almost all types of brain tumors produce symptoms that vary depending on the part of the brain involved. Symptoms include headaches, seizures, problems with vision, vomiting, and other mental changes.

Brain cancer is slightly different from a brain tumor. Brain cancer is a disease in which the cancer cells grow to form a mass cancer tissue that intervenes with other brain functions such as muscle control, sensation, memory & other body functions. Cancer cells developing from brain tissue are termed primary brain tumors while tumors that proliferate from other body parts to the brain are termed metastatic tumors.

Brain cancers are of different types, categorized into grades I, II, III, and IV. In Grade I, the tissue is benign and looks like normal brain cells with slower growth. In Grade II, the tissue is malignant, and the cells look like normal cells than in Grade I.

In Grade III, the malignant tissue has cells that look very different from normal cells. The abnormal cells are actively growing and have a distinctly abnormal appearance. In Grade IV, the malignant tissue has cells that look almost abnormal and often grow quickly. In the detection of brain cancer, symptomatic measures are carried out such as medical history and physical exam, imaging tests, MRI scans, CT scans, and PET scans. is carried out. Such tests determine the level of cell damage for further diagnosis.

On the basis of test type, the global brain cancer diagnostics market is segmented as Magnetic Resonance Spectroscopy, PET scan, single-photon emission CT scan (SPECT), spinal tap, and magnetic resonance imaging (MRI). On the basis of brain cancer type, the global market size for brain cancer diagnostics is segmented as acoustic neuroma, astrocytomas, chordomas, choroid plexus papilloma, craniopharyngiomas, ependymomas, ganglioneuromas, glioblastoma multiforme, gliomas, meningiomas, and others.

On the basis of end-user, the global brain cancer diagnostics market is segmented as hospitals, cancer diagnostics centers, and cancer research institutes. On the basis of treatment, the global market for brain cancer diagnostics is segmented as surgeries, radiation therapy, chemotherapy, immunotherapy, and targeted therapy. Surgeries are the most commonly used treatment for most brain cancers in which the tumor cells are removed, and further diagnosis is recommended. On the basis of geographic segmentation, the global market for cancer diagnostics spans North America, Latin America, Europe, Asia-Pacific, Middle East & Africa.

North America dominates the global market share owing to the presence of favorable reimbursement policies and advanced healthcare infrastructure. APAC regions are lucrative markets for the growth of brain cancer diagnostics owing to the presence of heavy unmet needs in emerging economies such as China and Japan. Researchers at the University of Illinois have found a way to deal with cancer cells. Researchers have used Graphene to differentiate a single hyperactive cancerous cell from a normal cell simply by interfacing it. The graphene system is capable of detecting the level of activity of the interfaced cells. Owing to its characteristics, Graphene is the most suitable and noninvasive tool for early cancer diagnosis. It is thin and is most sensitive to its surface conditions. The key players in the global market for the brain cancer diagnostics market include Hologic, Inc., NantOmics, GE Healthcare, Thermo Fisher Scientific, Inc., and Siemens Healthcare Diagnostics.